GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (XSWX:BSLN) » Definitions » Research & Development

Basilea Pharmaceutica (XSWX:BSLN) Research & Development : CHF77.9 Mil (TTM As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Basilea Pharmaceutica Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Basilea Pharmaceutica's Research & Development for the six months ended in Dec. 2023 was CHF56.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was CHF77.9 Mil.

Basilea Pharmaceutica Research & Development Historical Data

The historical data trend for Basilea Pharmaceutica's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Research & Development Chart

Basilea Pharmaceutica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 102.66 97.41 93.16 73.80 77.85

Basilea Pharmaceutica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.47 37.15 36.66 21.47 56.39

Basilea Pharmaceutica Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF77.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica  (XSWX:BSLN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Basilea Pharmaceutica Research & Development Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (XSWX:BSLN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (XSWX:BSLN) » Definitions » Research & Development
Comparable Companies
XSWX:IDIA XSWX:XLS XSWX:NWRN XSWX:MOLN XSWX:SANN XSWX:RLF XSWX:ADXN XSWX:EVE XSWX:KNRS XSWX:SPEX OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
BSLNz:UK
Address
Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058
Website
https://www.basilea.com
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (XSWX:BSLN) Headlines

No Headlines